Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study
…, D Dazzi, S Simonetta, P Bonara… - European journal of …, 2007 - academic.oup.com
… nor correlated with CD20+ depletion (P = NS). CAS values … (P < 0.0001) and more significantly
compared with IVGC (P < … (ANOVA; P < 0.0001) and those with lid signs (ANOVA; P < …
compared with IVGC (P < … (ANOVA; P < 0.0001) and those with lid signs (ANOVA; P < …
Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid …
…, I Campi, S Rossi, P Bonara… - European journal of …, 2006 - academic.oup.com
One patient with Graves' hyperthyroidism and ophthalmopathy in its active phase and
unresponsive to steroid, was treated with the anti-CD20 monoclonal antibody, rituximab (RTX), as …
unresponsive to steroid, was treated with the anti-CD20 monoclonal antibody, rituximab (RTX), as …
Serum hepcidin and macrophage iron correlate with MCP-1 release and vascular damage in patients with metabolic syndrome alterations
…, BM Motta, DW Swinkels, P Bonara… - … , and vascular biology, 2011 - Am Heart Assoc
… by ELISA, were correlated with hepcidin-25 measured by time-of-flight mass spectrometry
(P=0.005) and were an independent predictor of the presence of carotid plaques (P=0.05). …
(P=0.005) and were an independent predictor of the presence of carotid plaques (P=0.05). …
Relationship between anti-phospholipid and anti-endothelial cell antibodies III: beta 2 glycoprotein I mediates the antibody binding to endothelial membranes and …
N Del Papa, L Guidali, L Spatola, P Bonara… - Clinical and …, 1995 - europepmc.org
Objective To investigate the role of antibodies reacting with beta 2 glycoprotein I (beta 2GPI)
in the antiendothelial cell binding activity present in sera from patients with the anti-…
in the antiendothelial cell binding activity present in sera from patients with the anti-…
Small dose of rituximab for graves orbitopathy: new insights into the mechanism of action
…, N Currò, M Introna, S Rossi, P Bonara… - Archives of …, 2012 - jamanetwork.com
Methods. Patients with GO underwent rituximab infusion after premedication with
acetaminophen, chlorpheniramine maleate, and 100 mg of hydrocortisone sodium succinate. …
acetaminophen, chlorpheniramine maleate, and 100 mg of hydrocortisone sodium succinate. …
Unusual presentation of large B cell lymphoma: a case report and review of literature
…, M Barcella, IM Baldini, P Bonara… - Clinical & Laboratory …, 2006 - Wiley Online Library
Diffuse large B cell lymphoma (DLBCL) is the largest subtype of non‐Hodgkin's lymphomas
(NHLs) and is characterized by relatively frequent extranodal presentation. In these cases, …
(NHLs) and is characterized by relatively frequent extranodal presentation. In these cases, …
Serum BAFF concentrations in patients with Graves' disease and orbitopathy before and after immunosuppressive therapy
…, D Dazzi, A Maffini, I Campi, P Bonara… - The Journal of …, 2012 - academic.oup.com
… antithyroglobulin antibodies (P = 0.04… P = 0.02) but also at B cell repopulation (P = 0.04).
In patients treated with MP, serum BAFF concentrations decreased significantly after therapy (P …
In patients treated with MP, serum BAFF concentrations decreased significantly after therapy (P …
Rituximab treatment in patients with active Graves' orbitopathy: effects on proinflammatory and humoral immune reactions
…, N Currò, S Simonetta, P Bonara… - Clinical & …, 2010 - academic.oup.com
… P = not significant (ns)]. Serum CXCL10 increased after RTX at B cell depletion and at 30
weeks (P … to TRAb, nor did antibodies against orbital antigens (P = ns). In conclusion, this study …
weeks (P … to TRAb, nor did antibodies against orbital antigens (P = ns). In conclusion, this study …
Severity assessment of healthcare-associated pneumonia and pneumonia in immunosuppression
M Carrabba, M Zarantonello, P Bonara… - European …, 2012 - Eur Respiratory Soc
… p<0.05 for all tests, with the exception of the pairwise comparisons between AUCs. In this
case the threshold was set to p… than CAP (66.1% versus 51.9%; p<0.001) and were more often …
case the threshold was set to p… than CAP (66.1% versus 51.9%; p<0.001) and were more often …
Induction of CD69 activation molecule on human neutrophils by GM-CSF, IFN-γ, and IFN-α
…, M Schena, AM Ongari, M Carrabba, P Bonara… - Cellular …, 2002 - Elsevier
The CD69 glycoprotein is an early activation antigen of T and B lymphocytes but it expression
is induced in vitro on cells of most hematopoietic lineages, including neutrophils after …
is induced in vitro on cells of most hematopoietic lineages, including neutrophils after …